Skip to main content
Download PDF
Download ePub

Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation

Journal of Experimental & Clinical Cancer Research volume 39, Article number: 10 (2020) Cite this article

The Original Article was published on 26 November 2019

Correction to: J Exp Clin Cancer Res (2019) 38:474

https://doi.org/10.1186/s13046-019-1442-2

In the original publication of this article [1], labelling within Fig. 7a was incorrect. The updated figure is shown below, with ‘DMT1’ now corrected to read ‘DNMT1’.

Fig. 7
figure 1

IL-6 increases the expression of OCT4 through DNMT3b and IGF-1R activation in human HCC. a Model of how IL-6 increases theexpression of OCT4 through p-STAT3-DNMT3b-OCT4-DNMT1 activation in human HCC. b The combination use of nanaomycin and sorafenibsynergistically suppresses the cell proliferation of sorafenib resistant HCC cells

Full size image

The authors sincerely apologize for the inconvenience caused to the readers.

Reference

  1. Lai, et al. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res. 2019;38:474. https://doi.org/10.1186/s13046-019-1442-2.

Download references

Author information

Author notes

  1. Yu-Ting Su and Ching-Chi Chi contributed equally to this work.

Authors and Affiliations

  1. Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan

    Ssu-Chuan Lai, Yu-Ting Su, Yung-Che Kuo & Yen-Hua Huang

  2. Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan

    Ssu-Chuan Lai, Yu-Ting Su, Yung-Che Kuo & Yen-Hua Huang

  3. TMU Research Center for Cell Therapy and Regeneration Medicine, Taipei Medical University, Taipei, 11031, Taiwan

    Yu-Ting Su, Yung-Che Kuo, Yu-Chih Wu, Pei-Chi Lan & Yen-Hua Huang

  4. Department of Dermatology, Chang Gung Memorial Hospital, Linkou, Taoyuan, 33305, Taiwan

    Ching-Chi Chi

  5. College of Medicine, Chang Gung University, Taoyuan, 33302, Taiwan

    Ching-Chi Chi

  6. Department of Pathology, Chang Gung Memorial Hospital, Chiayi, 61363, Taiwan

    Kam-Fai Lee

  7. School of Respiratory Therapy, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan

    Yu-Chih Wu

  8. Institute of Clinical Medicine, College of Medicine, National Yang Ming University, Taipei, 11221, Taiwan

    Muh-Hwa Yang

  9. Division of Medical Oncology, Taipei Veterans General Hospital, Taipei, 11217, Taiwan

    Muh-Hwa Yang

  10. School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, 33382, Taiwan

    Te-Sheng Chang

  11. Division of Internal Medicine, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chiayi, 61363, Taiwan

    Te-Sheng Chang

  12. International PhD Program for Cell Therapy and Regeneration Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan

    Yen-Hua Huang

  13. Center for Reproductive Medicine, Taipei Medical University Hospital, Taipei Medical University, Taipei, 11031, Taiwan

    Yen-Hua Huang

  14. Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, 11031, Taiwan

    Yen-Hua Huang

  15. Comprehensive Cancer Center of Taipei Medical University, Taipei, 11031, Taiwan

    Yen-Hua Huang

Authors
  1. Ssu-Chuan Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Ting Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ching-Chi Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yung-Che Kuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kam-Fai Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yu-Chih Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pei-Chi Lan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Muh-Hwa Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Te-Sheng Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yen-Hua Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Te-Sheng Chang or Yen-Hua Huang.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lai, SC., Su, YT., Chi, CC. et al. Correction to: DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res 39, 10 (2020). https://doi.org/10.1186/s13046-019-1518-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13046-019-1518-z

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us